Table 5.
Associations with development of eGFR <30 mL/min in patients on tenofovir-containing ART from two South African clinics during the first 6 months on ART and after 6 months on ART
| 0–6 months |
>6 months |
|||||
|---|---|---|---|---|---|---|
| Baseline characteristics | n1 | Crude HR (95% CI) |
Adjusted2 HR (95% CI) n = 10 283 |
Crude HR (95% CI) |
Adjusted2 HR (95% CI) n = 10 283 |
|
| Age | Per 10-year increase | 14 633 | 1.5 (1.3 to 1.7) |
1.5 (1.3 to 1.8) |
1.4 (1.1 to 1.7) |
1.6 (1.2 to 2.2) |
| eGFR (reference ≥60 mL/min) | <60 mL/min | 13 003 | 7.2 (5.0 to 10.5) |
4.6 (2.9 to 7.2) |
1.5 (0.5 to 4.7) |
1.3 (0.4 to 4.3) |
| CD4 (reference ≥200 cells/µL) | 100–199 cells/µL | 11 686 | 1.8 (1.1 to 2.9) |
2.1 (1.2 to 3.5) |
0.8 (0.4 to 1.5) |
0.8 (0.4 to 1.6) |
| 50–99 cells/µL | 3.7 (2.2 to 6.0) |
4.1 (2.4 to 6.9) |
1.3 (0.6 to 2.9) |
1.2 (0.5 to 2.9) |
||
| <50 cells/µL | 6.2 (4.0 to 9.7) |
7.9 (4.9 to 12.9) |
2.4 (1.2 to 4.7) |
3.1 (1.5 to 6.4) |
||
| Weight (reference ≥60 kg) | <60 kg | 13 887 | 2.1 (1.6 to 2.8) |
1.6 (1.1 to 2.1) |
1.3 (0.8 to 2.0) |
1.2 (0.7 to 2.2) |
| Concomitant ARV (reference NNRTI) | PI | 14 571 | 1.9 (0.8 to 4.7) |
2.0 (0.5 to 8.2) |
2.8 (0.9 to 8.9) |
6.1 (1.4 to 25.6) |
1. Number of patients in the crude analyses.
2. Adjusted for treatment site and the other variables in the model.
CI: confidence interval; eGFR: estimated glomerular filtration rate; HR: hazard ratio; NNRTI: non-nucleoside reverse transcriptase inhibitor; PI: protease inhibitor.